A Phase 1 Open-Label, Multiple Dose, Dose Escalation Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma.
Phase of Trial: Phase I
Latest Information Update: 30 Oct 2013
At a glance
- Drugs Dalantercept (Primary)
- Indications Multiple myeloma; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Acceleron Pharma
- 26 Sep 2012 Planned End Date changed from 1 Aug 2012 to 1 Oct 2012 as reported by ClinicalTrials.gov.
- 18 Jun 2012 Planned End Date changed from 1 Oct 2011 to 1 Aug 2012 as reported by ClinicalTrials.gov.
- 13 Jun 2011 Planned end date changed from 1 May 2011 to 1 Oct 2011 as reported by ClinicalTrials.gov.